THC ther­a­py tanks in PhI, send­ing Zyner­ba's stock tum­bling yet again

Zyner­ba’s stock $ZYNE is get­ting crushed yet again af­ter news that its THC ther­a­py has flopped in a Phase I tri­al. At least this time, they’re find­ing out ear­ly.

The De­von, Penn­syl­va­nia-based com­pa­ny was test­ing its trans­der­mal patch meant to de­liv­er THC, the psy­choac­tive cannabi­noid in cannabis, as a pro-drug in healthy vol­un­teers. The hope was to make a THC ther­a­py that didn’t have to be tak­en oral­ly, which can cause high peak lev­els of THC in the blood caus­ing in­creased psy­choac­tive side ef­fects. Un­for­tu­nate­ly, the com­pa­ny wasn’t able to get ZYN001 to take. The Phase I study re­sults in­di­cat­ed that tar­get blood lev­els of 5 to 15 ng/ml THC were not achieved.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.